This real-world analysis utilizing the nationwide data from multiple reference oncology centers confirms that treatment with second-line BRAFi/MEKi therapy prolongs the survival of advanced/metastatic BRAF-mutated melanoma patients. Here, BRAF is linked to melanoma.